ClinicalTrials.gg
TerminatedNCT05643638Updated Oct 22, 2026

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

A Phase 2 interventional study of CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) and Placebo in Graft Versus Host Disease, Acute, sponsored by Cynata Therapeutics Limited. Terminated at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cynata Therapeutics Limited · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD.
Updated Oct 22, 2026Now TerminatedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Graft vs Host Disease with a site in United States — 49 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
75th of 389
65 · median 30
Started
2024
with 7 others
Phase 2
164 of 454
15 open now
Registered
416th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 75th largest by enrollment of the 389 interventional ones that give a count, is one of 8 that started in 2024, is one of 164 in phase 2, and was the 416th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

49 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.

03

Conditions studied

  • Graft Versus Host Disease, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergone hematopoietic stem cell transplant (HSCT)
  • Clinically diagnosed with acute GvHD requiring systemic therapy with .
  • HR-aGvHD must meet one of the following clinical features within 72 hours prior to randomization: (a) high-risk as per Refined Minnesota Criteria; OR (b) One of the following: (i) isolated stage 2 involvement of the lower GI tract; (ii) Stage 1 lower GI tract disease with skin involvement
  • Evidence of myeloid engraftment post allogeneic HSCT
  • of at least one month

Exclusion criteria

Exclusion Criteria:

  • Received any systemic treatment for aGvHD other than +/- calcineurin inhibitors
  • Chronic GvHD or overlap syndrome with both acute and chronic features of GvHD
  • primary since
  • received more than one HSCT
  • respiratory, renal or cardiac disease
  • Cholestatic disorders or sinusoidal obstructive syndrome/veno-occlusive disease of the liver
  • Any active uncontrolled infection requiring treatment and likely to impact on the ability of the subject to participate in the trial.
  • Known infection with CMV, EBV, HHV-6, , , or Tuberculosis. If the treatment for CMV, EBV, HHV-6, HBV, HCV has commenced the subject is eligible.
  • Known sensitivity to dimethylsulfoxide (DMSO) or any other component of CYP-001.
  • Received any treatment agent within 30 days or within 5 half-lives of Screening, whichever is greater.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    CYP-001 plus corticosteroids

    Biological: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) · Drug: Corticosteroids

  • Placebo comparator
    Placebo plus corticosteroids

    Biological: Placebo · Drug: Corticosteroids

Interventions

  • BiologicaliPSC-derived MSCs CYP-001Studies of iPSC-derived MSCs CYP-001iPSC-derived MSCs CYP-001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.

  • BiologicalPlacebo

    The placebo product is identical to CYP-001, except that it contains no active agent

  • DrugCorticosteroids

    All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the proportion of subjects demonstrating a complete response (CR) or partial response (PR) without requirement for additional systemic therapies for an earlier progression, a mixed response or a nonresponse.

    Time frame: 28 days

Secondary outcomes

  1. Durable Overall response rate (ORR)

    Durable ORR is defined as the proportion of subjects demonstrating OR at Day 28 and maintaining OR at Day 60 and Day 100

    Time frame: 100 days

  2. Overall response rate (ORR)

    ORR is defined as the proportion of subjects demonstrating a CR or PR without requirement for additional systemic therapies for an earlier progression, a mixed response or a nonresponse.

    Time frame: 100 days

  3. Complete response rate (CRR)

    ORR is defined as the proportion of subjects demonstrating a CR without requirement for additional systemic therapies for an earlier progression, a mixed response or a nonresponse.

    Time frame: 100 days

  4. Overall survival

    The Kaplan Meier curve will be used to estimate the distribution of overall survival and the probability of surviving to relevant timepoints.

    Time frame: 2 years

  5. Event-free survival

    Event-Free survival is defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause.

    Time frame: 2 years

  6. Time to non-relapse mortality

    Time to non-relapse mortality is defined as the time from the date of randomization to the date of death not preceded by hematologic disease relapse/progression.

    Time frame: 2 years

  7. Failure-free survival

    Failure-free survival is defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment

    Time frame: 2 years

  8. Time to malignancy relapse/progression

    Time to malignancy relapse/progression is defined as the time from the date of randomization to the date to hematologic malignancy relapse/progression.

    Time frame: 2 years

  9. Incidence of chronic GvHD

    Chronic GvHD is defined as the diagnosis of mild, moderate, or severe chronic GvHD.

    Time frame: 2 years

  10. Weekly cumulative steroid dose

    The total corticosteroid dose administered each week

    Time frame: 100 days

  11. Patient reported outcomes: Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT) instrument

    The FACT-BMT form was designed to measure the quality of life in patients undergoing bone marrow transplantation.

    Time frame: 2 years

  12. Patient reported outcomes: EuroQol 5-Dimension (EQ-5D) health-related quality of life instrument

    EQ-5D is a standardized measure of health-related quality of life

    Time frame: 2 years

  13. Incidence, severity, duration of treatment-emergent adverse events

    Assessment of safety

    Time frame: 2 years

07

Study locations

39 sites
  • Banner MD Anderson
    Phoenix, Arizona 85012, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85288, United States
  • University of Arkansas Medical Center
    Little Rock, Arkansas 72205, United States
  • Mayo Clinic Hospital
    Jacksonville, Florida 32224, United States
  • Memorial healthcare System
    Pembroke Pines, Florida 33026, United States
  • BMT Group of Georgia
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Evanston, Illinois 60208, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University Of Nebrasaka Medical Center
    Omaha, Nebraska 68198, United States
  • Weill Cornell Medicine - New York Presbyterian Hospital
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Penn State Health
    Hershey, Pennsylvania 17033, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Hospital Claude Huriez
    Lille, France
  • Hôpital Necker Enfants Malades
    Paris, France
  • Hôpital Universitaire Pitié-Salpêtrière
    Paris, France
  • Azienda Ospedaliero Universitaria delle Marche
    Ancona, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Italy
  • Istituto Clinico Humanitas
    Rozzano, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
  • Ospedale dell'Angelo di Mestre
    Venezia, Italy
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, Lithuania
  • ICO l'Hospitalet - Hospital Duran i Reynals
    Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Hospital Universitato De La Princesa
    Madrid, Spain
  • Hospital Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Clínica Universidad de Navarra
    Pamplona, Spain
  • Anadolu Medical Center
    Eskişehir, Turkey (Türkiye)
  • Gayrettepe Florence Nightingale Hastanesi
    Istanbul, 34318, Turkey (Türkiye)
  • Koc University
    Istanbul, Turkey (Türkiye)
  • Memorial Bahcelievler Hospital
    Istanbul, Turkey (Türkiye)
  • Izmir Medicalpark Hospital
    Izmir, Turkey (Türkiye)
  • İnonu University
    Malatya, Turkey (Türkiye)
  • Dr Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
    Yenimahalle, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — The Sponsor will consider requests to share IPD from this study for further research of a non-commercial nature. Requests should be submitted to clinical@cynata.com. Sharing of IPD will be subjects to the execution of an IPD sharing agreement, and applicable laws, regulations and guidance in force at that time.

Time frame: IPD sharing requests will be considered from 12 months after publication of results of this study.

Access criteria: Requests for sharing of IPD for non-commercial research purposes will be considered in good faith by the Sponsor. Requests must be accompanied by a detailed research plan, with a justification for the proposed research.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Mar 2026, 24 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Jun 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 9, 2022
StartActual
Mar 4, 2024
Primary completionActual
Mar 17, 2026
CompletionActual
Jun 17, 2026was Dec 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD.
changed Oct 22, 2026
Study completion
Dec 2027→Jun 17, 2026 (actual)
Oct 22, 2026
Enrollment
60 (estimated)→65 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Terminated
    Why stopped Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD.
    Study completion Dec 2027→Jun 17, 2026 (now actual)
    Enrollment 60 (estimated)→65 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05643638
Lead sponsor
Cynata Therapeutics Limited
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Mar 4, 2024
Primary completion
Mar 17, 2026
Completion
Jun 17, 2026
Last update
Oct 22, 2026

Study contacts

Jolanta Airey, MD
study director · Cynata Therapeutics Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: iPSC-derived MSCs CYP-001

Start the discussion